Top Markets
Coin of the day
StageZero Life Sciences Ltd. StageZero Life Sciences Ltd.

StageZero Life Sciences Ltd.

SZLS
Clasificación en acciones #36214
StageZero Life Sciences Ltd. is a vertically integrated healthcare enterprise... StageZero Life Sciences Ltd. is a vertically integrated healthcare enterprise specializing in the development and market release of advanced molecular diagnostic tests. These innovative solutions are designed for the proactive detection of diseases and individualized health management, with a particular emphasis on oncology-related conditions across North America. Central to its operations is the proprietary Sentinel Principle platform, which enables the identification of novel biomarkers directly from whole blood samples. Its flagship product, Aristotle, exemplifies this innovation; it's a comprehensive multi-cancer panel that simultaneously screens for numerous cancers from a single blood draw, boasting impressive sensitivity and specificity for each identified malignancy. Beyond Aristotle, the company's portfolio includes ColonSentry, a blood-based test gauging colorectal cancer risk; COVID-19 PCR testing and general blood analysis services; the Prostate Health Index for prostate cancer screening; and BreastSentry, designed to evaluate a woman's susceptibility to breast cancer. Established in 1998, StageZero Life Sciences Ltd. maintains its headquarters in Richmond Hill, Canada.
Precio por acción
$0.02770208
Última sincronización: 2025-03-10
Capitalización bursátil
$2.92M
Cambio (1 día)
-0.46%
Cambio (1 año)
0.00%
País
CA
Comercio StageZero Life Sciences Ltd. (SZLS)

Categoría

EPS de StageZero Life Sciences Ltd. (SZLS)
EPS a fecha de 2026 TTM: 0
Según los últimos informes financieros y el precio de las acciones de StageZero Life Sciences Ltd., el EPS actual de la empresa (TTM) es 0. Al final del año 2026, la empresa tenía un EPS de 0 igual a al EPS de 2026, que fue de 0.
Historial de EPS de StageZero Life Sciences Ltd. desde 2026 hasta 2026
EPS al final de cada año
Año EPS Cambiar
Not enough data for the provided dates.
EPS de empresas similares o competidoras